Study on the Effects of Raltegravir (Isentress) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms RALMET-VOLHCB
- 02 Apr 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Apr 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.
- 10 Mar 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.